Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
New England Journal of Medicine · 24.10.2024 · 391 (16) · 1486-1498
DOI: 10.1056/nejmoa2403614 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 24.10.2024. Verfasst von Byoung C Cho und 57 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Samsung Medical Center, Sungkyunkwan Uni…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 500-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Janssen Research & Development, LLC.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Samsung Medical Center, Sungkyunkwan University School of Medicine (S.-H.L.), and the Lung Cancer Center, Asan…
ORCID-Profile: Byoung C Cho, Antonio Passaro, Hidetoshi Hayashi
Förderung
- Janssen Research & Development, LLC
Zitieren
APA
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J. S., Lee, S. H., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Mourão Dias, J., Besse, B., Lee, K. H., Xiong, H., How, S. H., Cheng, Y., Chang, G. C., …, & MARIPOSA Investigators (2024). Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 391(16), 1486-1498. https://doi.org/10.1056/nejmoa2403614
Vancouver
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2024;391(16):1486-1498. doi:10.1056/nejmoa2403614
BibTeX
@article{Cho2024,
author = {Cho, Byoung C and Lu, Shun and Felip, Enriqueta and Spira, Alexander I and Girard, Nicolas and Lee, Jong-Seok and Lee, Se-Hoon and Ostapenko, Yurii and Danchaivijitr, Pongwut and Liu, Baogang and Alip, Adlinda and Korbenfeld, Ernesto and Mourão Dias, Josiane and Besse, Benjamin and Lee, Ki-Hyeong and Xiong, Hailin and How, Soon-Hin and Cheng, Ying and Chang, Gee-Chen and Yoshioka, Hiroshige and Yang, James C-H and Thomas, Michael and Nguyen, Danny and Ou, Sai-Hong I and Mukhedkar, Sanjay and Prabhash, Kumar and D'Arcangelo, Manolo and Alatorre-Alexander, Jorge and Vázquez Limón, Juan C and Alves, Sara and Stroyakovskiy, Daniil and Peregudova, Marina and Şendur, Mehmet A N and Yazici, Ozan and Califano, Raffaele and Gutiérrez Calderón, Vanesa and de Marinis, Filippo and Passaro, Antonio and Kim, Sang-We and Gadgeel, Shirish M and Xie, John and Sun, Tao and Martinez, Melissa and Ennis, Mariah and Fennema, Elizabeth and Daksh, Mahesh and Millington, Dawn and Leconte, Isabelle and Iwasawa, Ryota and Lorenzini, Patricia and Baig, Mahadi and Shah, Sujay and Bauml, Joshua M and Shreeve, S Martin and Sethi, Seema and Knoblauch, Roland E and Hayashi, Hidetoshi and MARIPOSA Investigators, MARIPOSA Investigators},
title = {Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {16},
pages = {1486--1498},
doi = {10.1056/nejmoa2403614}
}
EUVIMED